DSIP (Delta Sleep-Inducing Peptide): Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 15 sources cited
Overview
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated in 1977 from the blood of sleeping rabbits. It plays a central role in modulating sleep architecture, particularly promoting delta-wave (slow-wave) sleep — the most restorative phase of the sleep cycle. DSIP also demonstrates stress-protective, analgesic, and neuroendocrine-regulatory properties. It was studied in European clinics in the 1980s for insomnia and for alcohol and opiate withdrawal, but it never became an approved medicine and the research largely stopped.
Mechanism of Action
DSIP exerts its effects through multiple interacting neurochemical pathways, making it one of the more pharmacologically complex sleep-related peptides. Its mechanism was never established. The early reviews record effects on EEG activity, brain neurotransmitter levels, circadian and locomotor patterns and hormone levels, and proposed a modulation of adrenergic transmission; no study has shown that DSIP releases GABA or dampens glutamate signalling. Beyond direct neurotransmitter modulation, DSIP acts on the hypothalamic-pituitary-adrenal (HPA) axis. It reduces ACTH and cortisol secretion, effectively dampening the stress response that frequently disrupts sleep. This cortisol-lowering effect is one reason DSIP has attracted interest for stress-related insomnia specifically. In rats, DSIP partly blocked the rise in corticosterone caused by six hours of immobilisation, rather than lowering basal levels, and it did not change ACTH or beta-endorphin. DSIP has been proposed to act on opiate receptors, because the slow-wave sleep it induced in animals was reversed by naloxone. That hypothesis is why it was given to patients in alcohol and opiate withdrawal, where most of their symptoms eased. Early work reported that DSIP acts on the circadian rhythms of locomotor activity, brain transmitters and plasma cortisol, but no study has shown an action on the suprachiasmatic nucleus or on melatonin timing. A controlled study in healthy women found DSIP did not change growth hormone or prolactin secretion or their circadian rhythm, and no study has measured somatostatin or luteinizing hormone under it. Its interaction with serotonergic pathways is narrower than that: in rats under hypoxia DSIP limited stress-induced changes in brain serotonin and in monoamine oxidase A activity. In the small human studies DSIP did not suppress REM sleep and caused no daytime sedation; tolerance and dependence were never tested.
DSIP (Delta Sleep-Inducing Peptide) Benefits: What the Research Shows
- Schoenenberger and Monnier isolated DSIP from the blood of sleeping rabbits and showed in 1977 that the synthetic nonapeptide, alone among nine related peptides, enhanced delta and spindle EEG patterns when infused into rabbits' brain ventricles (PNAS, 1977)
- A placebo-controlled double-blind study by Schneider-Helmert (1987) in European Neurology gave 14 middle-aged chronic insomniacs DSIP for 7 nights and found better night sleep and better daytime alertness and performance
- Schneider-Helmert (1986) published results in European Neurology showing sleep normalised in 18 middle-aged and elderly chronic insomniacs given DSIP for a week, with the gains holding through a one-week follow-up
- Work by Iukhananov et al. (1990) showed DSIP partly blocked the rise in plasma corticosterone in rats immobilised for six hours, without changing ACTH or beta-endorphin
- A 1986 review in Peptides records that DSIP was being evaluated for insomnia, pain and withdrawal, and that its physiological functions and mechanism, possibly involving adrenergic transmission, remained unestablished
- Khvatova et al. (2003) published in Peptides that DSIP improved oxidative phosphorylation in rat brain mitochondria and fully prevented the drop in mitochondrial respiration caused by hypoxia
- In an open clinical series of 107 inpatients, intravenous DSIP relieved most alcohol and opiate withdrawal symptoms, with anxiety the slowest to settle and headache the only reported side effect (Dick et al., European Neurology, 1984)
- EEG studies in rabbits showed DSIP enhanced delta and spindle activity, while in cats the effect fell on REM sleep instead, and in human insomniacs REM rose slightly
- A 1987 case report in Deutsche Medizinische Wochenschrift described a woman with delayed sleep phase insomnia whose main sleep phase advanced by 5 hours during a week of DSIP under polygraphic control
- A controlled study in eight healthy women found DSIP did not change growth hormone or prolactin secretion, or their circadian rhythm (Psychoneuroendocrinology, 1993)
DSIP (Delta Sleep-Inducing Peptide) Dosage
- Standard dose: 100–200 mcg subcutaneous injection 30–60 minutes before bedtime
- Loading protocol: 100 mcg nightly for 5 consecutive nights, then every other night for maintenance
- Clinical European protocol: 25 to 30 nmol/kg intravenously, roughly 1.5 to 1.8 mg for an adult (hospital setting only)
- Cycle length: 2–4 weeks on, 1–2 weeks off to prevent receptor desensitization
- Intranasal administration: 300–500 mcg per nostril, 30 minutes before sleep (lower bioavailability, ~30%)
- For chronic insomnia: 100 mcg nightly for 10 days, assess response, then taper to every-other-night dosing
- May be combined with low-dose melatonin (0.5–1 mg) for synergistic circadian realignment
- Avoid dosing with stimulants, caffeine, or intense evening exercise as these counteract GABAergic effects
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
DSIP (Delta Sleep-Inducing Peptide) Side Effects & Safety
Known Side Effects
- Mild drowsiness upon waking if dose is too high — typically resolves with dose reduction
- Occasional headache during the first 2–3 days of use, especially at doses above 200 mcg
- Injection site irritation including minor redness or itching (transient, resolves within 30 minutes)
- Vivid dreams reported by some users, particularly during the first week
- Rare reports of mild nausea when administered on a full stomach
- Potential for mild hypotension due to cortisol-lowering effects — caution in those with low baseline blood pressure
- No tolerance, dependence or withdrawal syndrome was reported in the clinical studies, though none lasted more than about a week or set out to look for it
Safety Profile
DSIP was studied in European clinics in the 1980s in small groups, from 6 volunteers to 107 withdrawal inpatients, which reported it well tolerated; little has been published since. Tolerance, physical dependence and rebound insomnia were never tested, though in the week-long studies sleep stayed improved after the last dose rather than rebounding. It does not impair cognitive function, motor coordination, or next-day alertness at standard doses. No lethal dose figure for DSIP was found in the published literature, and the dose-response in animals was reported as U-shaped, so a larger dose is not necessarily a stronger one. Contraindications include pre-existing hypotension (due to cortisol-lowering effects), concurrent use of opioid medications (possible additive CNS depression), and pregnancy/breastfeeding (insufficient safety data). Those on anti-epileptic medications should use caution as DSIP modulates GABAergic tone. It is not recommended to combine DSIP with alcohol or sedative medications. Long-term safety data beyond 12 weeks of continuous use is limited, so cycling is recommended.
What to Expect
Week 1: Most users notice faster sleep onset (reduced latency by 15–30 minutes) within the first 2–3 nights. Sleep may feel deeper with fewer mid-night awakenings. Vivid dreams are commonly reported as slow-wave sleep increases. Some initial grogginess possible as the body adjusts. Weeks 2–3: Sleep architecture normalizes significantly. Users report waking feeling more refreshed with improved morning alertness. Daytime stress resilience often improves due to cortisol modulation. Deep sleep phases lengthen, and HRV data (if tracked) typically shows improvement. Week 4+: Full benefits are established. Chronic insomnia sufferers report the most dramatic improvement at this stage. Sleep quality gains often persist for 2–4 weeks after discontinuation, suggesting DSIP helps 'reset' underlying sleep regulatory mechanisms rather than merely inducing sedation. Upon cycling off, sleep quality typically remains improved for several weeks before gradually returning to baseline.
Common Stacks
Selank
Selank reduces anxiety and modulates GABA — combining with DSIP addresses both daytime anxiety and nighttime sleep quality for comprehensive circadian support
Epitalon
Epitalon restores pineal gland melatonin production, complementing DSIP's sleep-architecture improvements for a synergistic anti-aging sleep stack
Pinealon
Pinealon is a bioregulator targeting the pineal gland that supports melatonin synthesis, pairing naturally with DSIP's delta-wave promoting effects
Storage & Handling
Store lyophilized DSIP at -20°C for long-term storage (up to 24 months) or 2–8°C (refrigerated) for up to 6 months. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 3–4 weeks. DSIP is moderately sensitive to heat and light — always store in a dark container or wrapped in foil. Reconstitute gently by allowing bacteriostatic water to run down the vial wall; do not shake vigorously as this can degrade the peptide. Typical reconstitution: add 1–2 mL bacteriostatic water to a standard vial for easy dosing calculations.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987.
- Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol. 1986.
- Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981.
- Schneider-Helmert D, Gnirss F, Monnier M, et al. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981.
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977.
- Schoenenberger GA. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984.
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984.
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986.
- Dick P, Costa C, Fayolle K, et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984.
- Iukhananov RIu, Rozhanets VV, Mikhaleva II, et al. Analysis of the mechanism of the stress-protective action of delta sleep-inducing peptide. Biull Eksp Biol Med. 1990.
- Khvatova EM, Samartzev VN, Zagoskin PP, et al. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides. 2003.
- Khvatova EM, Rubanova NA, Prudchenko IA, et al. Effects of delta-sleep inducing peptide (DSIP) and some analogues on the activity of monoamine oxidase type A in rat brain under hypoxia stress. FEBS Lett. 1995.
- Giusti M, Carraro A, Porcella E, et al. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology. 1993.
- Schneider-Helmert D, Hermann E, Schoenenberger GA. The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia. Dtsch Med Wochenschr. 1987.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
Related Peptides
Track DSIP (Delta Sleep-Inducing Peptide) in Your Protocol
Log your DSIP (Delta Sleep-Inducing Peptide) doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free